FZD9 methylation is an independent predictor of prognosis in MDS/AML
| . | FZD9 methylation is associated with ≥ 5% blasts; P = .005 . | FZD9 methylation is not associated with chromosome 7 abnormalities; P = .54 . | FZD9 methylation is not associated with complex chr abnormalities; P = .84 . | |||
|---|---|---|---|---|---|---|
| Blasts < 5%, n = 58 . | Blasts ≥ 5%, n = 126 . | Normal chr7, n = 157 . | Abnormal chr7, n = 17 . | < 3 chr abnorm., n = 131 . | ≥ 3 chr abnorm., n = 43 . | |
| FZD9 unmethylated | 50% (29/58) | 29% (36/126) | 37% (58/157) | 29% (5/17) | 37% (48/131) | 35% (15/43) |
| FZD9 methylated | 50% (29/58) | 71% (90/126) | 63% (99/157) | 71% (12/17) | 63% (83/131) | 65% (28/43) |
| . | FZD9 methylation is associated with ≥ 5% blasts; P = .005 . | FZD9 methylation is not associated with chromosome 7 abnormalities; P = .54 . | FZD9 methylation is not associated with complex chr abnormalities; P = .84 . | |||
|---|---|---|---|---|---|---|
| Blasts < 5%, n = 58 . | Blasts ≥ 5%, n = 126 . | Normal chr7, n = 157 . | Abnormal chr7, n = 17 . | < 3 chr abnorm., n = 131 . | ≥ 3 chr abnorm., n = 43 . | |
| FZD9 unmethylated | 50% (29/58) | 29% (36/126) | 37% (58/157) | 29% (5/17) | 37% (48/131) | 35% (15/43) |
| FZD9 methylated | 50% (29/58) | 71% (90/126) | 63% (99/157) | 71% (12/17) | 63% (83/131) | 65% (28/43) |
| Chr 7 abnormalities and ≥ 5% blast are independent predictors of 12-mo survival by multivariate analysis. FZD9 methylation approaches significance. . | |
|---|---|
| Cox proportional hazards regression analysis . | P . |
| Blasts ≥5% | .019 |
| Chromosome 7 abnormality | <.001 |
| Complex chr abnormality | .17 |
| FZD9 methylation | .064 |
| Chr 7 abnormalities and ≥ 5% blast are independent predictors of 12-mo survival by multivariate analysis. FZD9 methylation approaches significance. . | |
|---|---|
| Cox proportional hazards regression analysis . | P . |
| Blasts ≥5% | .019 |
| Chromosome 7 abnormality | <.001 |
| Complex chr abnormality | .17 |
| FZD9 methylation | .064 |
The variables used in multivariate analysis were FZD9 methylation status, presence of chromosome 7 abnormalities, presence of complex chr abnormalities (≥ 3 abnormalities on cytogenetic analysis), and blasts ≥ 5%.
Chr indicates chromosome; and blasts %, bone marrow myeloblast percent.